<DOC>
	<DOCNO>NCT01552915</DOCNO>
	<brief_summary>The purpose study determine effectiveness Vyvanse compare Concerta adolescent Attention-deficit/Hyperactivity Disorder ( ADHD ) .</brief_summary>
	<brief_title>Effectiveness Vyvanse Compared Concerta Adolescents With Attention-deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Subject must 1317 year age , inclusive , time consent . Subject must weigh 79.5lb . The parent/LAR must available approximately 7:00AM ( ±2 hour ) dispense dose investigational product study duration . Subject , female , must negative serum beta human chorionic gonadotropin ( βHCG ) pregnancy test negative urine pregnancy test agree comply applicable contraceptive requirement protocol . Subject ADHDRSIV total score ≥28 . Subject able swallow capsule . Subject hypertension rest sit blood pressure less equal 135/85mmHg . Exclusion Criteria Subject current , control ( medication prohibit study ) uncontrolled , comorbid psychiatric diagnosis significant symptom significant comorbid Axis II disorder significant Axis I disorder ( post traumatic stress disorder , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , depressive anxiety disorder . Diagnosis conduct disorder . Oppositional defiant disorder exclusionary . Subject consider suicide risk , previously make suicide attempt , currently demonstrate active suicidal ideation . Subjects intermittent passive suicidal ideation necessarily exclude . Subject underweight overweight . Subject concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition . Mild , stable asthma exclusionary . Subject history seizure ( infantile febrile seizure ) , chronic current tic disorder , current diagnosis and/or know family history Tourette 's Disorder . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem may place him/her increase vulnerability sympathomimetic effect stimulant medication . Subject know family history sudden cardiac death ventricular arrhythmia . Subject clinically significant ECG clinically significant laboratory abnormality . Subject current abnormal thyroid function , define abnormal thyroid stimulate hormone ( TSH ) thyroxine ( T4 ) . Treatment stable dose thyroid medication least 3 month permit . Subject document allergy , hypersensitivity , intolerance amphetamine excipients investigational product . Subject document allergy , hypersensitivity , intolerance MPH excipients reference product . Subject fail fully respond adequate course ( ) ( dose duration ) MPH amphetamine therapy . Subject history suspect substance abuse dependence disorder ( exclude nicotine ) . Subjects lifetime history amphetamine , cocaine , stimulant abuse and/or dependence exclude . Subject positive urine drug result . Subject previously participate study another clinical study involve SPD489/NRP104 . Subject glaucoma . Subject required take anticipates need take medication CNS effect affect performance , sedate antihistamine decongestant sympathomimetics , monoamine oxidase inhibitor . Stable use bronchodilator inhaler exclusionary . Subject female pregnant lactating . Subject well control his/her current ADHD medication . Subject preexist severe gastrointestinal tract narrowing .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>ADHD</keyword>
</DOC>